Maximilian Alexander Zierke, Christine Rangger, Kimia Samadikhah, Andreas Martin Schmid, Roland Haubner
{"title":"68ga标记的糖肽作为肝功能成像的有效工具","authors":"Maximilian Alexander Zierke, Christine Rangger, Kimia Samadikhah, Andreas Martin Schmid, Roland Haubner","doi":"10.1021/acs.molpharmaceut.4c01453","DOIUrl":null,"url":null,"abstract":"<p><p>[<sup>99m</sup>Tc]Tc-GSA, an albumin-based glycoprotein, is routinely used in Japan to measure the asialoglycoprotein receptor (ASGR) density via single photon emission tomography. Here we describe the development of <sup>68</sup>Ga-labeled peptide-based alternatives. Peptides were assembled on a solid support using a fragment coupling strategy. Glycosylation was carried out via a click chemistry approach resulting in a set of three peptides with increasing amounts of d-galactose (<i>n</i> = 3, 6, and 9) as well as one glycopeptide bearing nine <i>N</i>-acetylgalactosamine residues. <sup>68</sup>Ga-labeling of all compounds could be achieved in high radiochemical yields (>95%). Radiotracers exhibited high hydrophilicity, good metabolic stability in human serum and protein binding between 12 and 22%. The IC<sub>50</sub> values improved in the series tri-, hexa-, and nonamer with an IC<sub>50</sub> of 50 ± 30 pM for the latter one. In analogy, the <i>in vivo</i> biodistribution studies revealed increased liver uptake in the series of [<sup>68</sup>Ga]Ga-<b>NODAGA-TriLysan</b> (9.4 ± 2.0% ID/g, 30 min p.i.), [<sup>68</sup>Ga]Ga-<b>NODAGA-HexaLysan</b> (55.5 ± 7.4% ID/g, 30 min p.i.), and [<sup>68</sup>Ga]Ga-<b>NODAGA-NonaLysan</b> (79.6 ± 8.0% ID/g, 30 min p.i.). [<sup>68</sup>Ga]Ga-NODAGA-GalNAc-NonaLysan reached comparable liver uptake to [<sup>68</sup>Ga]Ga-<b>NODAGA-NonaLysan</b>, but showed higher accumulation in nontarget organs. The impressive imaging properties of [<sup>68</sup>Ga]Ga-<b>NODAGA-NonaLysan</b> were also confirmed by the PET/MR imaging studies in mice. Hence, [<sup>68</sup>Ga]Ga-<b>NODAGA-NonaLysan</b> represents a new PET radiopharmaceutical with even better imaging properties than [<sup>99m</sup>Tc]Tc-GSA.</p>","PeriodicalId":52,"journal":{"name":"Molecular Pharmaceutics","volume":" ","pages":"1677-1685"},"PeriodicalIF":4.5000,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11881035/pdf/","citationCount":"0","resultStr":"{\"title\":\"<sup>68</sup>Ga-Labeled Glycopeptides as Effective Tools for Liver Function Imaging.\",\"authors\":\"Maximilian Alexander Zierke, Christine Rangger, Kimia Samadikhah, Andreas Martin Schmid, Roland Haubner\",\"doi\":\"10.1021/acs.molpharmaceut.4c01453\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>[<sup>99m</sup>Tc]Tc-GSA, an albumin-based glycoprotein, is routinely used in Japan to measure the asialoglycoprotein receptor (ASGR) density via single photon emission tomography. Here we describe the development of <sup>68</sup>Ga-labeled peptide-based alternatives. Peptides were assembled on a solid support using a fragment coupling strategy. Glycosylation was carried out via a click chemistry approach resulting in a set of three peptides with increasing amounts of d-galactose (<i>n</i> = 3, 6, and 9) as well as one glycopeptide bearing nine <i>N</i>-acetylgalactosamine residues. <sup>68</sup>Ga-labeling of all compounds could be achieved in high radiochemical yields (>95%). Radiotracers exhibited high hydrophilicity, good metabolic stability in human serum and protein binding between 12 and 22%. The IC<sub>50</sub> values improved in the series tri-, hexa-, and nonamer with an IC<sub>50</sub> of 50 ± 30 pM for the latter one. In analogy, the <i>in vivo</i> biodistribution studies revealed increased liver uptake in the series of [<sup>68</sup>Ga]Ga-<b>NODAGA-TriLysan</b> (9.4 ± 2.0% ID/g, 30 min p.i.), [<sup>68</sup>Ga]Ga-<b>NODAGA-HexaLysan</b> (55.5 ± 7.4% ID/g, 30 min p.i.), and [<sup>68</sup>Ga]Ga-<b>NODAGA-NonaLysan</b> (79.6 ± 8.0% ID/g, 30 min p.i.). [<sup>68</sup>Ga]Ga-NODAGA-GalNAc-NonaLysan reached comparable liver uptake to [<sup>68</sup>Ga]Ga-<b>NODAGA-NonaLysan</b>, but showed higher accumulation in nontarget organs. The impressive imaging properties of [<sup>68</sup>Ga]Ga-<b>NODAGA-NonaLysan</b> were also confirmed by the PET/MR imaging studies in mice. Hence, [<sup>68</sup>Ga]Ga-<b>NODAGA-NonaLysan</b> represents a new PET radiopharmaceutical with even better imaging properties than [<sup>99m</sup>Tc]Tc-GSA.</p>\",\"PeriodicalId\":52,\"journal\":{\"name\":\"Molecular Pharmaceutics\",\"volume\":\" \",\"pages\":\"1677-1685\"},\"PeriodicalIF\":4.5000,\"publicationDate\":\"2025-03-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11881035/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Molecular Pharmaceutics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1021/acs.molpharmaceut.4c01453\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/2/17 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular Pharmaceutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1021/acs.molpharmaceut.4c01453","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/17 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
摘要
[99mTc]Tc-GSA是一种基于白蛋白的糖蛋白,在日本通常通过单光子发射断层扫描来测量asialglyprotein receptor (ASGR)的密度。在这里,我们描述了基于68ga标记的肽基替代品的发展。利用片段耦合策略将多肽组装在固体支架上。糖基化通过点击化学方法进行,得到一组含有越来越多d-半乳糖(n = 3,6和9)的3个肽,以及一个含有9个n -乙酰半乳糖残基的糖肽。所有化合物的68ga标记可以在高放射化学产率(>95%)下实现。放射性示踪剂亲水性高,在人血清中代谢稳定性好,蛋白质结合率在12% ~ 22%之间。三聚氰胺、六聚氰胺和非聚氰胺的IC50值均有所提高,后者的IC50为50±30 pM。类似地,体内生物分布研究显示,[68Ga]Ga-NODAGA-TriLysan(9.4±2.0% ID/g, 30 min p.i), [68Ga]Ga-NODAGA-HexaLysan(55.5±7.4% ID/g, 30 min p.i)和[68Ga]Ga-NODAGA-NonaLysan(79.6±8.0% ID/g, 30 min p.i)系列药物的肝脏摄取增加。[68Ga]Ga-NODAGA-GalNAc-NonaLysan的肝脏摄取与[68Ga]Ga-NODAGA-NonaLysan相当,但在非靶器官的积累更高。小鼠PET/MR成像研究也证实了[68Ga]Ga-NODAGA-NonaLysan令人印象深刻的成像特性。因此,[68Ga]Ga-NODAGA-NonaLysan代表了一种新的PET放射性药物,具有比[99mTc]Tc-GSA更好的成像性能。
68Ga-Labeled Glycopeptides as Effective Tools for Liver Function Imaging.
[99mTc]Tc-GSA, an albumin-based glycoprotein, is routinely used in Japan to measure the asialoglycoprotein receptor (ASGR) density via single photon emission tomography. Here we describe the development of 68Ga-labeled peptide-based alternatives. Peptides were assembled on a solid support using a fragment coupling strategy. Glycosylation was carried out via a click chemistry approach resulting in a set of three peptides with increasing amounts of d-galactose (n = 3, 6, and 9) as well as one glycopeptide bearing nine N-acetylgalactosamine residues. 68Ga-labeling of all compounds could be achieved in high radiochemical yields (>95%). Radiotracers exhibited high hydrophilicity, good metabolic stability in human serum and protein binding between 12 and 22%. The IC50 values improved in the series tri-, hexa-, and nonamer with an IC50 of 50 ± 30 pM for the latter one. In analogy, the in vivo biodistribution studies revealed increased liver uptake in the series of [68Ga]Ga-NODAGA-TriLysan (9.4 ± 2.0% ID/g, 30 min p.i.), [68Ga]Ga-NODAGA-HexaLysan (55.5 ± 7.4% ID/g, 30 min p.i.), and [68Ga]Ga-NODAGA-NonaLysan (79.6 ± 8.0% ID/g, 30 min p.i.). [68Ga]Ga-NODAGA-GalNAc-NonaLysan reached comparable liver uptake to [68Ga]Ga-NODAGA-NonaLysan, but showed higher accumulation in nontarget organs. The impressive imaging properties of [68Ga]Ga-NODAGA-NonaLysan were also confirmed by the PET/MR imaging studies in mice. Hence, [68Ga]Ga-NODAGA-NonaLysan represents a new PET radiopharmaceutical with even better imaging properties than [99mTc]Tc-GSA.
期刊介绍:
Molecular Pharmaceutics publishes the results of original research that contributes significantly to the molecular mechanistic understanding of drug delivery and drug delivery systems. The journal encourages contributions describing research at the interface of drug discovery and drug development.
Scientific areas within the scope of the journal include physical and pharmaceutical chemistry, biochemistry and biophysics, molecular and cellular biology, and polymer and materials science as they relate to drug and drug delivery system efficacy. Mechanistic Drug Delivery and Drug Targeting research on modulating activity and efficacy of a drug or drug product is within the scope of Molecular Pharmaceutics. Theoretical and experimental peer-reviewed research articles, communications, reviews, and perspectives are welcomed.